Focus: iBio is a publicly traded pre-revenue biotech focused on antibody therapies for oncology and metabolic disorders. With 1-50 employees and only $225K in FY2025 revenue, it operates as a clinical-stage company with three Phase 1 programs.
Profile data last refreshed 57m ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
iBio offers high-risk, high-reward early-stage exposure suitable only for scientists comfortable with pre-clinical uncertainty and significant dilution risk; capital runway and lack of revenue traction warrant serious due diligence.
Help build intelligence for iBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from iBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pharos iBio to Showcase AI, Quantum Computing Drug-Discovery Strategy at BIO KOREA 2026 - aju press
Pharos iBio to Showcase AI, Quantum Computing Drug-Discovery Strategy at BIO KOREA 2026 aju press
IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia - MSN
IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia MSN
IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia - MSN
IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia MSN
Jones Trading reiterates iBio stock rating on obesity drug data - Investing.com
Jones Trading reiterates iBio stock rating on obesity drug data Investing.com
Pharos iBio to Discuss Leukemia Drug Licensing at Bio China - Seoul Economic Daily
Pharos iBio to Discuss Leukemia Drug Licensing at Bio China Seoul Economic Daily
8-K Filing: iBio, Inc. (IBIO) (CIK 0001420720) — EX-99.1
EX-99.1
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo